Evaluation of the effects of testosterone and luteinizing hormone on regulation of β-amyloid in male 3xTg-AD mice
- PMID: 22587890
- PMCID: PMC3399667
- DOI: 10.1016/j.brainres.2012.05.011
Evaluation of the effects of testosterone and luteinizing hormone on regulation of β-amyloid in male 3xTg-AD mice
Abstract
During normal aging, men experience a significant decline in testosterone levels and a compensatory elevation in levels of gonadotropin luteinizing hormone (LH). Both low testosterone and elevated LH have been identified as significant risk factors for the development of Alzheimer's disease (AD) in men. It is unclear whether changes in testosterone or LH primarily underlie the relationship with AD, and therefore may be a more suitable therapeutic target. To examine this issue, we compared levels of β-amyloid (Aβ) immunoreactivity in male 3xTg-AD mice under varying experimental conditions associated with relatively low or high levels of testosterone and/or LH. In gonadally intact mice, Aβ accumulation increased after treatment with the gonadotropin-releasing hormone agonist leuprolide, which inhibits the hypothalamic-pituitary-gonadal (HPG) axis and reduces both testosterone and LH levels. In gonadectomized (GDX) mice with low testosterone and high LH, we also observed increased Aβ levels. Treatment of GDX mice with testosterone significantly reduced Aβ levels. In contrast, leuprolide did not significantly decrease Aβ levels and moreover, inhibited the Aβ-lowering effect of testosterone. Evaluation of hippocampal-dependent behavior revealed parallel findings, with performance in GDX mice improved by testosterone but not leuprolide. These data suggest that Aβ-lowering actions of testosterone are mediated directly by androgen pathways rather than indirectly via regulation of LH and the HPG axis. These findings support the clinical evaluation of androgen therapy in the prevention and perhaps treatment of AD in hypogonadal men.
Copyright © 2012 Elsevier B.V. All rights reserved.
Conflict of interest statement
The authors disclose no conflicts of interest.
Figures




Similar articles
-
Testosterone regulation of Alzheimer-like neuropathology in male 3xTg-AD mice involves both estrogen and androgen pathways.Brain Res. 2010 Nov 4;1359:281-90. doi: 10.1016/j.brainres.2010.08.068. Epub 2010 Aug 31. Brain Res. 2010. PMID: 20807511 Free PMC article.
-
Androgens regulate the development of neuropathology in a triple transgenic mouse model of Alzheimer's disease.J Neurosci. 2006 Dec 20;26(51):13384-9. doi: 10.1523/JNEUROSCI.2514-06.2006. J Neurosci. 2006. PMID: 17182789 Free PMC article.
-
The gonadotropin connection in Alzheimer's disease.Endocrine. 2005 Apr;26(3):317-26. doi: 10.1385/ENDO:26:3:317. Endocrine. 2005. PMID: 16034187 Review.
-
Sex differences in luteinizing hormone aggravates Aβ deposition in APP/PS1 and Aβ1-42-induced mouse models of Alzheimer's disease.Eur J Pharmacol. 2024 May 5;970:176485. doi: 10.1016/j.ejphar.2024.176485. Epub 2024 Mar 15. Eur J Pharmacol. 2024. PMID: 38492878
-
The impact of luteinizing hormone and testosterone on beta amyloid (Aβ) accumulation: Animal and human clinical studies.Horm Behav. 2015 Nov;76:81-90. doi: 10.1016/j.yhbeh.2015.05.020. Epub 2015 Jun 27. Horm Behav. 2015. PMID: 26122291 Review.
Cited by
-
Supraphysiologic-dose anabolic-androgenic steroid use: A risk factor for dementia?Neurosci Biobehav Rev. 2019 May;100:180-207. doi: 10.1016/j.neubiorev.2019.02.014. Epub 2019 Feb 25. Neurosci Biobehav Rev. 2019. PMID: 30817935 Free PMC article. Review.
-
Testosterone deficiency worsens mitochondrial dysfunction in APP/PS1 mice.Front Aging Neurosci. 2024 May 1;16:1390915. doi: 10.3389/fnagi.2024.1390915. eCollection 2024. Front Aging Neurosci. 2024. PMID: 38752208 Free PMC article.
-
Chronological Molecular Changes in Neuronal Communication in Androgen-Deficient Rats.J Mol Neurosci. 2019 Sep;69(1):83-93. doi: 10.1007/s12031-019-01335-7. Epub 2019 May 21. J Mol Neurosci. 2019. PMID: 31114953
-
Sexual Dimorphism in the 3xTg-AD Mouse Model and Its Impact on Pre-Clinical Research.J Alzheimers Dis. 2021;80(1):41-52. doi: 10.3233/JAD-201014. J Alzheimers Dis. 2021. PMID: 33459720 Free PMC article. Review.
-
Changes in cerebral metabolic activity in men undergoing androgen deprivation therapy for non-metastatic prostate cancer.Prostate Cancer Prostatic Dis. 2018 Sep;21(3):394-402. doi: 10.1038/s41391-018-0037-x. Epub 2018 Apr 27. Prostate Cancer Prostatic Dis. 2018. PMID: 29700388 Free PMC article.
References
-
- Ahlbom E, Prins GS, Ceccatelli S. Testosterone protects cerebellar granule cells from oxidative stress-induced cell death through a receptor mediated mechanism. Brain Research. 2001;892:255–262. - PubMed
-
- Almeida TA, Papadopoulos N. Progression model of prostate cancer. Methods Mol Biol. 2003;222:211–222. - PubMed
-
- Almenara A, Escalante G, Gazzo E, Gonzales GF. Transillumination to evaluate spermatogenesis: effect of testosterone enanthate in adult male rats. Arch Androl. 2001;46:21–27. - PubMed
-
- Ayata M, Yamane T, Okamoto S, Kitamura Y, Matsumoto K. Effect of long term androgen removal on androgen-induced proliferation of seminal vesicle cells in adult mice. J Steroid Biochem. 1987;28:399–403. - PubMed
-
- Ayata M, Yamane T, Li W, Terada N, Kitamura Y, Matsumoto K. Proliferative response of seminal vesicle cells to androgen in mice castrated neonatally and pretreated with estrogen or androgen at adulthood. Endocrinol Jpn. 1988;35:511–515. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases